Not all patient respond the same to drugs, IMU is seeing this in their current clinical trials and that's why there are multiple drugs from multiple BP offered for the same cancer treatment. We need multiple alternate drugs which are safe so patients can safely swap to other treatment if their current treatment isn't working as effective as for others. If you don't think an IP which open a market to 90% of solid cancer market as being "dominate" then I don't know what to tell you.
Not all patient respond the same to drugs, IMU is seeing this in...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $112.0M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.6¢ | 1.4¢ | $125.4K | 8.369M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 76 | 17029463 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 1061875 | 3 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |